Cellectis (NASDAQ:CLLS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, Zacks.com reports. The firm currently has a $15.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price suggests a potential upside of 12.95% from the company’s previous close.
According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. “
Several other brokerages have also recently commented on CLLS. ValuEngine upgraded Cellectis from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. BidaskClub upgraded Cellectis from a “sell” rating to a “hold” rating in a report on Tuesday. BTIG Research initiated coverage on Cellectis in a report on Friday, August 9th. They set a “buy” rating and a $37.00 target price on the stock. Finally, Goldman Sachs Group set a $20.00 price target on Cellectis and gave the company a “hold” rating in a report on Monday, August 12th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $31.33.
A number of institutional investors have recently bought and sold shares of CLLS. Cubist Systematic Strategies LLC bought a new position in Cellectis in the second quarter valued at about $103,000. Aperio Group LLC bought a new position in Cellectis in the second quarter valued at about $147,000. A.R.T. Advisors LLC bought a new position in Cellectis in the second quarter valued at about $171,000. OneAscent Financial Services LLC bought a new position in Cellectis in the second quarter valued at about $257,000. Finally, D. E. Shaw & Co. Inc. bought a new position in Cellectis in the second quarter valued at about $502,000. Institutional investors and hedge funds own 32.13% of the company’s stock.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Recommended Story: What is the Coverage Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.